Before The Bell
FONT-SIZE Plus   Neg

Pharmacyclics Inc. (PCYC) Leaped To A New High After NDA Submission

Trade PCYC now with 

Pharmacyclics Inc. (PCYC: Quote) announced Wednesday morning that it has submitted a New Drug Application to the FDA for the investigational oral Bruton's tyrosine kinase inhibitor, ibrutinib, for two relapsed/refractory B-cell malignancy indications: mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma.

Pharmacyclics gapped up Wednesday and climbed sharply during the first hour of trade. The stock ended the day with a gain of 10.74 at $100.26 on above average volume. Pharmacyclics surged past resistance and set a new high for the year.

Click here to receive FREE breaking news email alerts for Pharmacyclics Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback:

Business News

comments powered by Disqus